Volkswagen's excess emissions will lead to 1,200 premature deaths in Europe

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide between 2008 and 2015. The devices were designed to detect and adapt to laboratory tests, making the cars appear to comply with environmental standards when, in fact, they emitted pollutants called nitric oxides, or NOx, at levels that were on average four times the applicable European test-stand limit.

While Volkswagen has issued recalls of affected vehicles in both the U.S. and Europe, scientists at MIT and elsewhere have found the excess emissions has already had an impact on public health. The team previously estimated that the excess emissions generated by 482,000 affected vehicles sold in the U.S. will cause approximately 60 premature deaths across the U.S.

Now the researchers have looked closer to Volkswagen's home base, examining the health impact from the 2.6 million affected cars sold in Germany under Volkswagen Group's brands VW, Audi, Skoda, and Seat. In a paper published today in Environmental Research Letters, the team reports that the manufacturer's emissions in excess of the test-stand limit value have had a significant effect on public health not just in Germany but across Europe.

The researchers estimate that 1,200 people in Europe will die early, each losing as much as a decade of their life, as a result of excess emissions generated between 2008 and 2015 by affected cars sold in Germany. Of these premature deaths, 500 will likely occur in Germany, meaning that more than 60 percent of premature mortalities stemming from those German-sold cars will occur in neighboring countries, most notably Poland, France, and the Czech Republic.

"Air pollution is very much transboundary," says co-author Steven Barrett, the Leonardo-Finmeccanica Associate Professor of Aeronautics and Astronautics at MIT. "[Pollution] doesn't care about political boundaries; it just goes straight past. Thus, a car in Germany can easily have significant impacts in neighboring countries, especially in densely populated areas such as the European continent."

If Volkswagen can recall and retrofit affected vehicles to meet European standards by the end of 2017, this would avert 2,600 additional premature deaths, or 29,000 life years lost, and 4.1 billion Euros in corresponding health costs, which would otherwise be expected in the absence of a recall.

Barrett's co-authors from MIT are lead author and graduate student Guillaume Chossière, postdoc Akshay Ashok, research assistant Irene Dedoussi, and research scientist Raymond Speth. Sebastian Eastham of Harvard University and Robert Malina of Hasselt University in Belgium are also co-authors.

Something in the air
Barrett says that it's not surprising that Germany, and Europe as a whole, incur higher health impacts from Volkswagen's excess emissions, as compared to the U.S. Not only were more affected cars sold in Germany (2.6 million) than in the U.S. (482,000), differences in population density, driving behavior, and atmospheric conditions also help explain the aggravated health impacts across Europe.

For instance, Europe's average population density is about three times higher than the U.S. average, and historical data has shown that diesel cars in Germany are driven on average 20 percent more, in terms of annual mileage, compared to the average American car that was considered in the U.S. study. In other words, there are more affected cars on the road, generating emissions that affect a higher concentration of people.

Atmospheric conditions play a role, as well. NOx is emitted from the engine as a gas, which can be carried by winds over long distances before or while reacting with ammonia in the air to form fine particulates. Since the atmosphere in Europe happens to contain more ammonia than in the U.S., more fine particulates may form from a given amount of NOx. It is exposure to these fine particulates which has been shown to cause cardiopulmonary and respiratory disease. NOx emissions also contribute to the formation of ozone, another pollutant known to be detrimental to human health.

"It takes time for NOx to get converted into particulates, at which point, they could be 100 to 200 kilometers or further away from their source," Barrett says.

Excess emissions' health effects
The researchers arrived at their mortality estimates using a method similar to the one they adopted to assess Volkswagen's health impacts in the U.S. The team based their analysis in part on the German Federal Motor Transport Authority's measurements of emissions from Volkswagen cars.

They then used historical data on driving behavior in Germany to estimate the number of kilometers driven by each car per year and where drivers were likely to drive the most. From that, the researchers generated a map of excess emissions within Germany.

Barrett and his colleagues worked this emissions map into a simulation of the atmosphere, modeling where the NOx emissions traveled, given prevailing winds, temperature, and precipitation, and where the gas interacted with other compounds to form fine particulates and ozone.

The atmospheric models produced a map of fine particulates and a map of ozone, which the team then overlaid on population density maps across Europe. With these maps, they calculated people's exposure to Germany-derived excess emissions, for each country in the European Union. From these exposure estimates, the researchers calculated the increased risk of dying early in the population, using a "concentration response function" - a relationship between a person's exposure to a given dose of a pollutant and the person's related health risk.

"It ends up being about a one percent extra risk of dying early in a given year, per microgram per meter cubed of fine particles you're exposed to," Barrett says. "Typically that means that someone who dies early from air pollution ends up dying about a decade early."

Volkswagen and beyond
Overall, the researchers found that 1,200 premature deaths will likely occur as a result of excess emissions that have already been released into the atmosphere between 2008 and 2015. Of these, 500 early deaths occur in Germany, followed by 160 in Poland, 84 in France, and 72 in the Czech Republic, with the remainder split among other European countries.

The researchers performed the same analysis a second time, under a scenario in which Volkswagen fixes affected cars to meet regulatory standards by the end of 2017, generating no excess emissions starting in January 2018. Under this scenario, the company would avert 2,600 premature deaths, or 29,000 years of life lost.

Going forward, the researchers plan to expand their study of auto emissions' health impact, concentrating on diesel vehicles in Europe.

"It seems unlikely that Volkswagen is the only company with issues with excess emissions," Barrett says. "We don't know if other manufacturers have these defeat devices, but there is already evidence that many other vehicles in practice emit more than the applicable test-stand limit value. So we're trying to do this for all diesel vehicles."

Guillaume P Chossière, Robert Malina, Akshay Ashok, Irene C Dedoussi, Sebastian D Eastham, Raymond L Speth, Steven R H Barrett.
Public health impacts of excess NOx emissions from Volkswagen diesel passenger vehicles in Germany.
Environ. Res. Lett. 12 (2017) 034014, http://iopscience.iop.org/1748-9326/12/3/034014

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]